Interaction Checker

Neomycin interactions

Neomycin (Neo-Fradin), an aminoglycoside has 56 documented interactions across the FDA labels and fact sheets we index: 33 major, 15 moderate, 8 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Major interactions (33)

  • Acetazolamidecarbonic anhydrase inhibitorMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Amiloridepotassium-sparing diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • BacitracinantibioticMajor

    Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Neomycin label, Boxed warning)

  • Bisoprolol and hydrochlorothiazidebeta blockerMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Bumetanideloop diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • CalciumVitamin and mineralMajor

    If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Neomycin label, Boxed warning)

  • Chlorthalidonethiazide diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Dicloxacillinpenicillin antibioticMajor

    In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. (Dicloxacillin label, Drug interactions)

  • Eplerenonealdosterone antagonistMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Ethacrynic acidloop diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Felodipinedihydropyridine calcium channel blockerMajor

    If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Neomycin label, Boxed warning)

  • Furosemideloop diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • GentamicinaminoglycosideMajor

    Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Neomycin label, Boxed warning)

  • Hydrochlorothiazidethiazide diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Indapamidethiazide diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Isradipinedihydropyridine calcium channel blockerMajor

    If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Neomycin label, Boxed warning)

  • KetamineCNS depressantMajor

    The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Neomycin label, Boxed warning)

  • Lisinopril and hydrochlorothiazideACE inhibitorMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Losartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Metolazonethiazide diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Nifedipinedihydropyridine calcium channel blockerMajor

    If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Neomycin label, Boxed warning)

  • Nisoldipinedihydropyridine calcium channel blockerMajor

    If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. (Neomycin label, Boxed warning)

  • OnabotulinumtoxinAneuromuscular blockerMajor

    The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Neomycin label, Boxed warning)

  • Polymyxin B and trimethoprim ophthalmicantibioticMajor

    Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Neomycin label, Boxed warning)

  • PropofolCNS depressantMajor

    The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Neomycin label, Boxed warning)

  • Spironolactonealdosterone antagonistMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Spironolactone and hydrochlorothiazidealdosterone antagonistMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • TobramycinaminoglycosideMajor

    Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Neomycin label, Boxed warning)

  • Torsemideloop diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Triamterenepotassium-sparing diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Triamterene and hydrochlorothiazidepotassium-sparing diureticMajor

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • Valsartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Major

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomycin label, Boxed warning)

  • VancomycinantibioticMajor

    Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Neomycin label, Boxed warning)

Moderate interactions (15)

  • ApixabananticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • DabigatrananticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • Digoxindigitalis glycosideModerate

    Therefore, digoxin serum levels should be monitored. (Neomycin label, Drug interactions)

  • EdoxabananticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • Emtricitabine and tenofovirantiretroviralModerate

    Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (Emtricitabine and tenofovir label, Drug interactions)

  • EnoxaparinanticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • FondaparinuxanticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • HeparinanticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • MycophenolateimmunosuppressantModerate

    Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing MYHIBBIN… (Mycophenolate label, Drug interactions)

  • Phytonadione (vitamin K1)vitamin KModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • RivaroxabananticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • SirolimusimmunosuppressantModerate

    Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. (Sirolimus label, Warnings and precautions)

  • TacrolimusimmunosuppressantModerate

    The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (Tacrolimus label, Warnings and precautions)

  • Vitamin KVitamin and mineralModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

  • WarfarinanticoagulantModerate

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomycin label, Drug interactions)

Minor mentions (8)

  • Amoxicillinpenicillin antibioticMinor

    Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Neomycin label, Drug interactions)

  • Amoxicillin and clavulanatepenicillin antibioticMinor

    Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Neomycin label, Drug interactions)

  • Ampicillinpenicillin antibioticMinor

    Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Neomycin label, Drug interactions)

  • MethotrexateimmunosuppressantMinor

    Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Neomycin label, Drug interactions)

  • Penicillin Gpenicillin antibioticMinor

    Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Neomycin label, Drug interactions)

  • Penicillin Vpenicillin antibioticMinor

    Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Neomycin label, Drug interactions)

  • Pyridostigminecholinesterase inhibitorMinor

    Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (Pyridostigmine label, Drug interactions)

  • Vitamin B12Vitamin and mineralMinor

    Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. (Neomycin label, Drug interactions)

Check Neomycin against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.